Categories: CareCauseDevelopmentFirmHealthTechInvestmentManagementMedtechResearchWebsite
Founded in 2019, NewAmsterdam Pharma is a clinical stage company focused on the research and development of transformative therapies for cardio-renal diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.
Investors 8
Funding Rounds 2
Date | Series | Amount | Investors |
05.06.2023 | - | $181.6M | - |
14.01.2021 | Series A | $196M | - |
Mentions in press and media 8
Date | Title | Description | Source |
12.03.2024 | NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Cl... | - | globenewsw... |
13.02.2024 | NewAmsterdam Pharma Announces Pricing of $175.3 Million Publ... | NAARDEN, the Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.... | forbion.co... |
26.08.2023 | Blooming Innovation: 15 Cutting-Edge Biotechnology Startups ... | Table of Contents show
1 Introduction
2 New Amsterdam Pharma: Revolutionizing Cardio-Metabolic The... | eustartup.... |
29.06.2022 | NewAmsterdam Pharma and the Menarini Group Sign Licensing De... | - Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular dise... | en.prnasia... |
29.12.2021 | These are the 21 biggest funding rounds of 2021 in the Nethe... | Over the last decade, the startup ecosystem’s value in the Netherlands has been rising fast. With a ... | siliconcan... |
18.01.2021 | NewAmsterdam Pharma lands $196M Series A | NewAmsterdam Pharma, a developer of therapies for cardio-metabolic diseases, has raised $196 million... | pitchbook.... |
14.01.2021 | NewAmsterdam Pharma Closes $196M Series A Funding | NewAmsterdam Pharma (NAP), a Naarden, the Netherlands-based clinical stage company focused on the re... | finsmes.co... |
14.01.2021 | Forbion portfolio company, NewAmsterdam Pharma completes €16... | Naarden, the Netherlands, and Munich, Germany, January 14 2021 – Forbion, a leading European life sc... | forbion.co... |
Reviews 0